Axogen Inc (AXGN)
$11.26 0.37 (3.18%)
11:59 EDT AXGN Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 429.54M
PE Ratio -31.28
Volume (Avg. Vol.) 90,791
Day's Range 11.04 - 11.74
52-Week Range 7.16 - 18.84
Dividend & Yield N/A (N/A)
AXGN Stock Predictions, Articles, and Axogen Inc News
- From InvestorPlace
- From the Web
By Ken Trester
I am recommending a bearish trade on AxoGen Inc. (NASDAQ:AXGN), a company that provides surgical products and education to help improve surgical treatment algorithms for peripheral nerve injuries.
The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.
The grades of 10 Health Care Equipment & Supplies stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
The following stocks were moving the Manufacturing sector today.
These 10 names aren't just hot stocks -- they're jaw-dropping, millionaire-making stocks that have earned four-digit returns over the past decade.
The grades of 9 Health Care Equipment & Supplies stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
From Market News Video
Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers
From Seeking Alpha
Gainers: Arrowhead Pharmaceuticals (NASDAQ:ARWR) +46%, Myomo (NYSEMKT:MYO) +38%, AxoGen (NASDAQ:AXGN) +15%, Covetrus (NASDAQ:CVET) +14%, Inovio Pharmaceuticals (NASDAQ:INO) +13%.Losers: Novus Therapeutics (NASDAQ:NVUS) -13%, Jounce Therapeutics (NASDAQ:JNCE) -10%, Syneos Health (NASDAQ:SYNH) -7%, Verastem (NASDAQ:VSTM) -5%, Evogene (NASDAQ:EVGN) -5%.
From Seeking Alpha
AxoGen (NASDAQ:AXGN) shares spike +23% after hours following the announcement of higher revenue guidance for third quarter.The company says it now expects Q3 revenue to be "at least" $30M, above the market estimate of $23.04M. AxoGen initially expected its Q3 revenue to remain below the prior-year levels of $28.6M.Upside on quarterly revenue guidance points to the lower than expected impact of regional COVID-19 resurgence on the incidence of trauma and surgical procedure, told AxoGen.
Navellier RatingsPowered by Portfolio Grader